Navigation Links
FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease
Date:9/30/2013

elerate the development of OMS824 and recognizes the important work conducted at Omeros," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "The manifestations of Huntington's are devastating to both Huntington's patients and their families, yet there is only one currently approved therapeutic and it is focused on a single symptom of the disease. OMS824 holds the promise of expanding treatment across the constellation of debilitating effects of Huntington's. We look forward to working with the FDA to advance the clinical evaluation of OMS824 in patients suffering from Huntington's disease and plan to initiate enrollment in a Phase 2 trial later this year."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Schizophrenia is a group of severe brain disorders characterized by an abnormal interpretation of reality, which can manifest as delusions, hallucinations, and/or disordered thinking and behavior. Cognitive dysfunction is responsible for substantial disability in both of these diseases and is not meaningfully improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve the motor and psychiatric abnormalities in Huntington's disease as well as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics targeting inflam
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Nektar Announces that FDA Grants Fast Track Designation to NKTR-181, a New Oral Opioid Analgesic Molecule, for the Treatment of Moderate to Severe Chronic Pain
2. Community Foundation Announces $2.6 Million In Grants From Centinela Medical Funds
3. U.S. FDA Grants Priority Review to the New Drug Application for Bayers Regorafenib to Treat Patients with Metastatic Colorectal Cancer
4. European Commission Grants Orphan Medicinal Product Designation for Emmaus Medicals Sickle Cell Treatment
5. FDA Grants Orphan Drug Designation To GeNO LLC For Use Of Inhaled Nitric Oxide In Treatment Of Persistant Pulmonary Hypertension Of The Newborn (PPHN)
6. Rep. Fattah Announces More Than $10.7 Million in Grants for Neuroscience, Scientific and Medical Research in Philadelphia
7. U.S. FDA Grants Priority Review to Bedaquiline (TMC207) for Multi-Drug Resistant Tuberculosis Treatment
8. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
9. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
10. As Global Telemedicine Market Reaches $2.5 Billion, Industry Leaders Gather in San Diego to Discuss Grants, Funding, Vendor Selection, Credentialing, and More
11. Nektar Announces that FDA Grants Fast Track Designation to Etirinotecan Pegol (NKTR-102) for the Treatment of Metastatic Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DALLAS , Dec. 23, 2014  Lockton ... operation of Lockton Companies, announced the addition of ... Foerster will join Lockton Dunning,s Pharmacy Consulting team, ... years of relevant industry experience to the position.  ... Managed Market Sales at Diplomat Specialty Pharmacy, where ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/24/2014)... and RALEIGH, N.C. , ... of Endo International plc (NASDAQ: ENDP ) ... BDSI ) announced today that they have submitted ... Film to the U.S. Food and Drug Administration (FDA).  ... management of pain severe enough to require daily, around-the-clock, ...
Breaking Medicine Technology:Kim Foerster Joins Lockton Companies 2TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5
... Core Essence Orthopaedics, Inc., a medical device company ... the extremities, has introduced their novel, surgeon-designed PONTiS™ Knotless ... the American Society for Surgery of the Hand (ASSH). ... to the upper and lower extremity markets, Core Essence ...
... 9, 2011 The Board of the European ... it agreed to ratify the proposal of the US Food ... designed with the help of EFCG and US industry representatives, ... Fees Act (GDUFA). GDUFA requires the FDA to ...
Cached Medicine Technology:Core Essence Orthopaedics Unveiled New Flexor Tendon Repair System at ASSH 2011 2European Fine Chemicals Group Ratifies FDA's Proposed Generic Drug User Fees Act (GDUFA) 2
(Date:12/26/2014)... 26, 2014 Cooking and warming ... out of 5. This score reflects slightly positive negotiation ... product specialization, low switching costs and a low level ... the low availability of substitutes for cooking and warming ... steel and aluminum, key inputs in the production process ...
(Date:12/26/2014)... 26, 2014 Plugin and template developers from ... 5 Plugin for Final Cut Pro X. , “TransPack Volume ... tool to pull off an industry professional look” Said Christina ... hands on TransPack Volume 5, a new level of professionalism ... set of over 50 Final Cut Pro X transitions featuring ...
(Date:12/26/2014)... 26, 2014 Pentec Health, Inc. number ... state of Pennsylvania for 2014. The awards program, created ... of its kind in the country. The program is ... Department of Community and Economic Development, the Pennsylvania State ... the Central Penn Business Journal. , Charlie ...
(Date:12/25/2014)... The microscopy market is estimated ... reach $5,756.0 million by 2019. Optical microscopy is ... electron microscopes product segment is expected to show ... Rising focus on nanotechnology, technological advancements, and increasing ... market. , Get Full Copy of Report @ ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
Breaking Medicine News(10 mins):Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3Health News:Today a new plugin was announced from Pixel Film Studios, TransPack Volume 5 for Final Cut Pro X 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... OAK BROOK, Ill., April 22 The ... of Minnesota have agreed to conditions for ... receive certain services from DeCare Dental following ... certain business functions that DeCare previously performed ...
... patient medical bill clearinghouse is set to help more than 50 ... patient medical debt. IOUSOS™, Powered by GlobeFunder and GlobalTech Collection ... way to deal with aged, unpaid patient bills now totaling an ... ...
... of Driver Technology to Power Artificial Heart Presented at ISHLT ... ... (Vocus) April 22, 2009 -- On April 22-25, SynCardia Systems, ... introduced the new 12-lb Freedom™ discharge driver at the International ...
... Illinois-based leader in physical therapy, fitness, and performance services, recently reached ... Chicago,s Hyde Park neighborhood and 51st center in suburban Naperville. ... ... AthletiCo , an Illinois-based leader in physical therapy, fitness, ...
... clinical supply chain management, announced today that Daniel C. Lubin, a Managing ... www.mhsinc.com , ... Fairfield, Connecticut (PRWEB) April 22, 2009-- ... clinical supply chain management, announced today that Daniel C. Lubin, a Managing ...
... to providing people with skin care information from ... and helpful insights are provided by skin care ... cosmetic dermatology. The content is written by experts ... of practical advice. Key portions of the service ...
Cached Medicine News:Health News:Delta Dental Plans Association and Delta Dental of Minnesota Agree to Conditions Regarding Supplier 2Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 2Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 3Health News:IOUSOS™ Launches Online Consumer Medical Bill Clearinghouse: New Service Set to Help More than 50 Million Americans and Healthcare Providers 4Health News:SynCardia Introduces New 12-lb Freedom Discharge Driver ,Designed to Provide Quality 'Lifestyle' for Total Artificial Heart Patients 2Health News:Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center 2Health News:Illinois-Based AthletiCo Opens Milestone 50th Physical Therapy Center 3Health News:Daniel C. Lubin Joins Management Health Solutions, Inc. Board of Directors 2Health News:Beauty-Doctors Website Provides Dermatologist-Authored Skin Care Information from Experts 2
... breadth of infectious disease ELISA products make ... standard assay protocols for faster integration into ... products provide increased reliability and run-to-run consistency. ... detection assays for a wide range of ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... infectious disease ELISA products make us a ... protocols for faster integration into the busy ... increased reliability and run-to-run consistency. Our Infectious ... for a wide range of serological assays ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
Medicine Products: